Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [683]

Research highlights in gastrointestinal tumours

Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA

Research highlights in gastrointestinal tumours ( Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA )

Updates from ASCO 2024 in gastrointestinal tumours

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center...

Updates from ASCO 2024 in gastrointestinal tumours ( Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA )

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than...

Prof David Tougeron - Poitiers University Hospital, Poitiers, France

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2...

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )

Administering systemic chemotherapy improves survival for patients with...

Dr Giacomo Bregni - Francis Crick Institute, London, England

Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )

Immunotherapy significantly increases the number of patients free from bowel...

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

Combination of cabozantinib and atezolizumab shows moderate activity in...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

More from ecancer